Boston Scientific Corp (BSX)vsIntegra LifeSciences Holdings (IART)
BSX
Boston Scientific Corp
$42.98
-0.28%
HEALTHCARE · Cap: $62.29B
IART
Integra LifeSciences Holdings
$15.50
-0.26%
HEALTHCARE · Cap: $1.21B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 1174% more annual revenue ($21.00B vs $1.65B). BSX leads profitability with a 17.5% profit margin vs -0.4%. BSX appears more attractively valued with a PEG of 0.60. BSX earns a higher WallStSmart Score of 72/100 (B).
BSX
Strong Buy72
out of 100
Grade: B
IART
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-10.0%
Fair Value
$39.07
Current Price
$42.98
$3.91 premium
Margin of Safety
+85.8%
Fair Value
$79.01
Current Price
$15.50
$63.51 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.3B in free cash flow
Reasonable price relative to book value
Growing faster than its price suggests
Areas to Watch
Distress zone — elevated risk
0.8% revenue growth
0.4% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 17.5% and operating margin at 22.9%. PEG of 0.60 suggests the stock is reasonably priced for its growth.
Bull Case : IART
The strongest argument for IART centers on Price/Book, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
The primary concerns for BSX are Altman Z-Score.
Bear Case : IART
The primary concerns for IART are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.94 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a mature stock while IART is a turnaround play — different risk/reward profiles.
IART carries more volatility with a beta of 1.21 — expect wider price swings.
BSX is growing revenue faster at 7.5% — sustainability is the question.
BSX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
BSX scores higher overall (72/100 vs 50/100), backed by strong 17.5% margins. IART offers better value entry with a 85.8% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Integra LifeSciences Holdings
HEALTHCARE · MEDICAL DEVICES · USA
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?